LABOPHARM GRANTS GLAXO ONCE-DAILY TRAMADOL RIGHTS IN MEXICO

May 31, 2006

Labopharm Inc. (DDSS) has granted GlaxoSmithKline (GSK) exclusive rights to distribute its once-daily tramadol product in Mexico. The Laval, Que. pharmaceutical company said the agreement expands the existing licensing and distribution arrangement between it and Glaxo, entered into in September 2005, for 20 Latin American and Caribbean countries.
MarketWatch

KEYWORDS FDAnews Drug Daily Bulletin

FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

LABOPHARM GRANTS GLAXO ONCE-DAILY TRAMADOL RIGHTS IN MEXICO

Upcoming Events

Organizing Data and Document Archives: Finding a Needle in a Haystack for FDA Inspections

Califf’s Post-PDUFA, Post-COVID FDA Agenda: Key Developments, Insights and Analysis

Building a World-Class Pharmaceutical Advertising and Promotion Review Program

The FDA’s Focus on Clinical Data Integrity Throughout Product Development and Approval

FDA’s New Quality Management System Regulation: What the Proposed Harmonization with ISO 13485 Means for Devicemakers

1st Annual Quality Management vSummit

Featured Products

FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

AngioDynamics Gets Expanded Clearance for Auryon Atherectomy System

Aura Biosciences Receives Fast Track Designation for Bladder Cancer Candidate

FDA Issues Update on Becton Dickinson’s Recall

FDA Grants Accelerated Approval to Enhertu for HER2-Mutant NSCLC

The Revised ICH E8: A Guide to New Clinical Trial Requirements